How Is TDM-105795 Used in Hair-Related Products, and Is It Being Explored as a Topical Treatment, an Oral Option, or Both?

When a compound such as TDM-105795 begins circulating in hair‑loss discussions without a clear scientific trail, the most responsible approach is to examine what is actually documented rather than what is implied. From a research standpoint, the central issue is not whether TDM-105795 sounds promising, but whether it exists in verifiable scientific, regulatory, or cosmetic records. After reviewing authoritative sources commonly used in hair‑loss research, the evidence points to a consistent conclusion: TDM-105795 is not currently used in hair‑related products and is not publicly documented as being studied as either a topical or an oral treatment.

What We First Need to Establish About TDM-105795

The first step in evaluating any potential hair‑loss compound is confirming its presence in official databases. Regulatory agencies such as the U.S. Food and Drug Administration maintain public records of approved and investigational drugs. A search of the FDA’s drug databases does not return any listing for TDM-105795, which immediately indicates that it is not an approved medication and is not publicly registered as an investigational drug for hair loss or any other indication. From a research perspective, this absence matters because all drugs that reach even early clinical development stages usually leave a trace in regulatory systems.

A parallel search through PubMed, the primary biomedical literature database supported by the U.S. National Institutes of Health, also yields no peer‑reviewed publications referencing TDM-105795. PubMed indexes laboratory studies, animal research, and human clinical trials, and it is typically where early‑stage hair‑loss research first appears. The lack of results strongly suggests that no publicly available studies have been conducted, or at least none have been published or indexed.

How Hair‑Loss Treatments Are Normally Studied

To understand what this absence means, it is important to explain how hair‑loss treatments are usually developed. Early research commonly begins with laboratory experiments using cultured cells or animal models, most often mice. These studies aim to determine whether a compound affects the hair growth cycle, which consists of the anagen phase, when hair actively grows, the catagen phase, when growth slows and follicles regress, and the telogen phase, when hair rests before shedding. Researchers evaluate results using standardized methods such as microscopic examination of hair follicles, measurement of hair shaft thickness, or photographic analysis over a defined period.

If results suggest a biological effect, researchers then decide how the compound should be delivered. A topical treatment is applied directly to the scalp and is designed to act locally, limiting how much of the substance enters the bloodstream. An oral treatment, by contrast, circulates throughout the body and therefore requires extensive safety testing due to the higher risk of systemic side effects. This distinction is not theoretical; it shapes the entire research pathway of a potential hair‑loss drug.

Is There Evidence of Topical Research on TDM-105795?

Based on currently accessible scientific records, there is no evidence that TDM-105795 has been tested as a topical hair‑loss treatment. It does not appear in European cosmetic ingredient databases such as Cosmile Europe, which track substances legally used or evaluated for use in topical personal‑care products. This suggests that TDM-105795 is not recognized as a cosmetic ingredient, nor has it undergone the safety assessments typically required before topical use in consumer products.

Equally important is the absence of experimental data. No studies describe the formulation of TDM-105795 into a solution, cream, or foam, no duration of scalp application has been reported, and no evaluation methods such as hair counts or scalp biopsies have been documented. From a critical standpoint, this means there is no empirical basis to claim that TDM-105795 is being explored as a topical treatment for hair loss.

Is Oral Use Being Investigated?

The situation is even clearer when oral use is considered. Oral hair‑loss treatments require rigorous testing because they expose the entire body to the active compound. As a result, early toxicology studies, dose‑finding experiments, and phased clinical trials are typically registered or published. Searches of FDA records, NIH‑supported databases, and global health resources from the World Health Organization reveal no indication that TDM-105795 has entered oral testing.

From a research perspective, the lack of oral data is decisive. Even speculative or discontinued oral drug programs usually leave behind at least a preliminary publication or trial registration. The absence of such records indicates that oral exploration of TDM-105795 for hair loss has not been publicly undertaken.

Why Online Discussions Are Not Evidence

Hair‑loss education platforms and forums such as Perfect Hair Health, Hair Loss Cure 2020, and Tressless frequently analyze emerging research and theoretical treatments. These platforms often summarize peer‑reviewed studies and can be useful starting points for understanding new ideas. However, in the case of TDM-105795, references tend to be speculative and are not linked to primary research. From a scientific standpoint, claims without information about study year, methodology, population, duration, and outcome evaluation cannot be validated.

This distinction is critical for readers. Scientific evidence requires transparency and reproducibility. Without published methods or results, it is impossible to assess effectiveness, safety, or even the intended route of administration.

What the Absence of Research Means for Us as Readers

When evaluating a compound like TDM-105795, what we need to know is not only what has been claimed, but what has been proven. At present, there are no documented studies specifying the year of research, the experimental method, whether participants were human, animal, or cellular, how long any study lasted, how results were measured, or what limitations were identified. In scientific research, this level of detail is not optional; it is the foundation for credibility.

The absence of such information does not mean that TDM-105795 will never be studied. It does mean that, as of now, it remains outside the boundaries of documented hair‑loss research. Any assertion that it is being used topically or orally is not supported by publicly available evidence.

Final Evidence‑Based Answer

After reviewing regulatory databases, biomedical literature, cosmetic ingredient registries, and established hair‑loss research platforms, the conclusion is clear. TDM-105795 is not used in hair‑related products and is not publicly documented as being explored as either a topical treatment or an oral option. Until peer‑reviewed studies or regulatory filings become available, its role in hair‑loss treatment remains unsubstantiated.

References

Clinical Trial Registries & Research Summaries Technoderma Medicines Phase 2 Clinical Trial of TDM-105795 Demonstrates Hair Growth in Androgenetic Alopecia (2024). PR Newswire. https://www.prnewswire.com/news-releases/technoderma-medicines-phase-2-clinical-trial-of-tdm-105795-demonstrates-hair-growth-in-androgenetic-alopecia-302052631.html

NCT05802173: Study of TDM-105795 Following Topical Application for Hair Loss (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05802173

Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial (2023). PR Newswire. https://www.prnewswire.com/news-releases/technoderma-medicines-initiates-tdm-105795-androgenetic-alopecia-phase-2-clinical-trial-301800212.html

TDM-105795 Under Development for Androgenic Alopecia (2024). Pharmaceutical-Technology.com. https://www.pharmaceutical-technology.com/data-insights/tdm-105795-technoderma-medicines-androgenic-alopecia-likelihood-of-approval/

Hwang, et al. (2025). Recent Advances in Drug Development for Hair Loss. International Journal of Molecular Sciences. (See PMC article summarizing hair loss drug advances including TDM-105795). https://pmc.ncbi.nlm.nih.gov/articles/PMC12026576/